Altria Group to FDA: Clarify Concerns About Nicotine

Date:

The tobacco giant is concerned over the FDA’s nicotine messaging and what they view as misconceptions about the substance.

Richmond, Va.-based Altria Group asked the Food and Drug Administration and its Center for Tobacco Products to clarify the agency’s position on nicotine.

CSP Daily News reports that Altria wants the Center for Tobacco Products to “correct the deeply entrenched public misperceptions regarding the health risks of nicotine.”

This favor was asked by Paige Magness, Altria’s senior vice president of regulatory affairs, via a letter directly addressed to CTP director Mitch Zeller.

“Left unaddressed, these widespread nicotine misperceptions could discourage adult smokers from switching to non-combustible tobacco products that may present lower health risk as compared to combustible cigarettes,” Magness said in a letter.

Read full article here.

Michael McGrady – VapingPost – March 18, 2021.

Want More Investigative Content?

Curate RegWatch
Curate RegWatchhttps://regulatorwatch.com
In addition to our original coverage, RegWatch curates top stories on issues and impacts arising from the regulation of economic, social and environmental activity in Canada and the U.S.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

MORE VAPING

Real Threat | Health Minister Unravels Canada’s Tobacco Strategy | RegWatch

Canadian Federal Health Minister Mark Holland is launching a crusade against safer nicotine products, driven by the uncompromising stance of non-profit health groups vehemently...

Vaping Coverage Get it NOW!

Sign Up for Incisive Content!

RegWatch original video is designed to move opinion. Get our videos first and be the first to share.

Your Information will never be shared with any third party